Patients who have had an myocardial infarction or evidence of left ventricular<unk>  are at considerable risk of developing heart<unk>  even if they do not present with any symptoms of heart<unk> . Reducing the risk of additional injury and retarding the evolution and progression of LV<unk>  is thus very important in considerably decreasing the incidence of heart<unk> . Initial appropriate measures include those listed as Class 1 recommendations for patients in Stage A.
The use of nutritional supplements in patients with a recent or remote MI with or without LV<unk>  has not been proved to reduce the risk of heart<unk> .
The aldosterone antagonist eplerenone on the other hand has been shown to reduce morbidity and mortality in patients with low ejection fraction and heart<unk>  after an MI that has already been treated with ACEIs and beta blockers.
Congestive heart failure treatment of patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms 
Congestive heart failure Pharmacological treatments for patients with heart failure with reduced ejection fraction
Congestive heart failure treatment of patients at high risk for developing heart failure 
Congestive heart failure treatment of patients with current or prior symptoms of heart failure 
Class III recommendations in guidelines for cardiovascular medicine list of guidelines
Congestive heart failure Treatment of Heart failure with preserved ejection fraction
Unstable angina / non ST elevation myocardial infarction long-term medical therapy and secondary prevention ACC/AHA guidelines quality care and outcomes
Acute kidney injury primary prevention